{
  "source": "PA-Notification-Tazverik.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1312-6\nProgram Prior Authorization/Notification\nMedication Tazverik® (tazemetostat)\nP&T Approval Date 3/2020, 3/3021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nTazverik (tazemetostat) is a methyltransferase inhibitor indicated for the treatment of adults and\npediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma\nnot eligible for complete resection, adult patients with relapsed or refractory follicular lymphoma\nwhose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who\nhave received at least 2 prior systemic therapies, or adult patients with relapsed or refractory\nfollicular lymphoma who have no satisfactory alternative treatment options.\nThese indications are approved under accelerated approval based on overall response rate and\nduration of response. Continued approval for these indications may be contingent upon\nverification and description of clinical benefit in a confirmatory trial(s).\nThe National Cancer Comprehensive Network (NCCN) also recommends the use of Tazverik in\nclassic follicular lymphoma as preferred second-line therapy irrespective of EZH2 mutation status\nfor older or infirm patients, or third-line and subsequent therapy (if not previously given)\nirrespective of EZH2 mutation status in patients with indications for treatment who have\nrelapsed/refractory disease.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients ",
    "tates also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tazverik will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Epithelioid Sarcoma\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Tazverik will be approved based on all of the following criteria:\n(1) Diagnosis of epithelioid sarcoma\n-AND-\n(2) Disease is one of the following\n(a) Metastatic\n(b) Locally advanced\n-AND-\n(3) Disease is not eligible for complete resection\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tazverik will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tazverik therapy.\nAuthorization will be issued for 12 months.\nC. Follicular Lymphoma\n1. Initial Authorization\na. Tazverik will be approved based on both of the following criteria:\n(1) Diagnosis of relapsed or refractory follicular lymphoma\n-AND-\n(2) One of the following:\n(a) Subsequent therapy in EZH2 mutation positive disease after 2 prior therapies\n(b) Second-line therapy irrespective of EZH2 mutation status for older or infirm\npatients with indications for treatment (i.e., other therapy options are not\nexpected to be tolerable)\n(c) Third-line and/or subsequent therapy (if not previously given) irrespective of\nEZH2 mutation status in patients with indications for treatment\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tazverik will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(1) Patient does not show evidence of progressive disease while on Tazverik therapy.\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensi",
    "ease while on Tazverik therapy.\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Tazverik [package insert]. Cambridge, MA: Epizyme, Inc. August 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org. Accessed February 12, 2025.\nProgram Prior Authorization/Notification - Tazverik\nChange Control\n3/2020 New program.\n3/2021 Annual review. Added coverage criteria for new indication for\nfollicular lymphoma. Updated references.\n3/2022 Annual review. Added unknown EZH2 mutation status to criteria per\nNCCN guidelines. Updated references.\n3/2023 Annual review with no changes to coverage criteria. Added state\nmandate footnote and updated references.\n3/2024 Annual review. Added NCCN recommendations to background section.\nAdded criteria to relapsed/refractory follicular lymphoma based on\nNCCN recommendations. Updated references.\n3/2025 Annual review with no changes to coverage criteria. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}